Whether it's Congress making decisions or venture capitalists making investments, leaving things to the last minute seems to be all the rage these days. Read More
Transcription activator-like effector nucleases, or TALENs, were named as one of the year's most exciting developments in Science magazine's 2012 list of top scientific advances, and 2013 began with another advance in the area of genome editing. Read More
Labrys Biologics Inc. burst on the biotech scene with a $31 million Series A, a new president and CEO and the acquisition of a Phase II-ready anti-calcitonin gene-related peptide (CGRP) humanized monoclonal antibody (MAb) from Pfizer Inc. to treat chronic migraine. Read More
• Synageva BioPharma Corp., of Lexington, Mass., initiated an underwritten public offering of 1.7 million shares of common stock, seeking to raise up to $80 million. Read More
• Icon Bioscience Inc., of Sunnyvale, Calif., said melphalan intraocular injection, its investigational product for treating retinoblastoma, was granted orphan designation by the FDA. Read More
• TheraVida Inc., of Mountain View, Calif., reported Phase II results showing that lead candidate Tolenix (THVD-201) produced statistically significant improvements in overactive bladder and urge urinary incontinence symptoms over placebo, and patients experienced efficacy similar in magnitude to the maximum dose of active control Detrol (2 mg tolterodine, administered twice daily). Read More
• Forest Laboratories Inc., of New York, said it entered a settlement agreement with Mumbai, India-based Glenmark Pharmaceuticals Ltd., and its affiliates, related to patent infringement litigation brought by Forest in response to Glenmark's abbreviated new drug application (ANDA) seeking to market generic versions of Forest's Bystolic (nebivolol) tablets. Read More
